REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B

Regeneron Pharmaceuticals balance sheet 1990–2026

Regeneron Pharmaceuticals had 9.30B USD in cash and short-term investments on 30 September 2026, against total debt of 2.71B USD: net cash of 6.59B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
3.66B3.12B2.49B2.73B3.11B2.89B2.19B1.62B1.47B812.73M535.20M
Short-term investments
5.64B5.49B6.52B8.11B4.64B2.81B1.39B1.60B1.34B596.85M503.48M
9.30B8.61B9.01B10.84B7.74B5.69B3.59B3.21B2.81B1.41B1.04B
Cash growth
+10.16%-4.52%-16.90%+40.07%+35.96%+58.76%+11.60%+14.39%+99.34%+35.71%-0.63%
Receivables
7.58B5.74B6.21B5.67B5.33B6.04B4.11B2.79B2.24B1.97B1.61B
Inventory
2.89B3.20B3.09B2.58B2.40B1.95B1.92B1.42B1.15B726.14M399.36M
Other current assets
0.00474.80M349.20M386.60M0.000.000.000.000.000.000.00
Total current assets
20.80B18.02B18.66B19.48B15.88B14.01B9.78B7.69B7.96B5.60B3.91B
Property, plant and equipment
5.73B5.12B4.60B4.15B3.76B3.48B3.22B2.89B2.58B2.36B2.08B
Long-term investments
9.56B10.26B8.90B5.40B6.59B6.84B3.14B3.26B1.76B1.49B864.26M
Goodwill and intangibles
1.32B1.26B1.15B1.04B915.50M6.70M—————
Intangible assets
1.32B1.26B1.15B1.04B915.50M6.70M—————
Other non-current assets
2.47B1.82B1.14B444.10M336.40M216.10M168.10M144.70M127.40M77.90M20.29M
Total assets
44.41B40.56B37.76B33.08B29.21B25.43B17.16B14.81B11.73B8.76B6.97B
Accounts payable
1.14B939.00M789.50M606.60M589.20M564.00M475.50M418.10M218.20M178.20M134.98M
Deferred revenue
749.80M553.00M627.70M458.90M477.90M442.00M577.70M591.70M452.50M320.14M231.66M
Short-term debt
0.000.000.000.000.000.000.000.000.000.000.00
Other current liabilities
0.000.000.000.000.000.000.0085.00M0.000.001.18M
Total current liabilities
6.20B4.37B3.94B3.42B3.14B3.93B2.70B2.10B1.44B1.14B1.24B
Long-term debt
1.99B1.99B1.98B1.98B1.98B1.98B1.98B0.000.000.000.00
Other non-current liabilities
2.50B2.02B1.57B854.10M638.00M680.20M687.10M799.70M546.60M949.29M100.39M
Lease obligations, current
720.00M0.000.000.000.00719.70M0.000.000.000.00129.56M
Lease obligations, long-term
0.00720.00M720.00M720.00M720.00M0.00717.20M713.90M708.50M703.50M351.57M
Total liabilities
10.91B9.30B8.41B7.11B6.55B6.67B6.14B3.72B2.98B2.62B2.52B
Common stock and paid-in capital
100.00K100.00K100.00K100.00K100.00K100.00K100.00K100.00K100.00K112.00K110.00K
Retained earnings
39.47B35.80B31.67B27.26B23.31B18.97B10.89B7.38B5.25B2.95B1.75B
Accumulated other comprehensive income
-197.50M77.50M-7.90M-80.90M-238.80M-26.20M29.30M21.10M-12.30M640.00K-12.84M
Shareholders' equity
33.50B31.26B29.35B25.97B22.66B18.77B11.03B11.09B8.76B6.14B4.45B
Minority interest
0.000.000.000.000.000.000.000.000.000.000.00
2.71B2.71B2.70B2.70B2.70B2.70B2.70B713.90M708.50M703.45M481.13M
Net cash
6.59B5.90B6.31B8.14B5.04B3.00B891.30M2.50B2.10B706.13M557.56M
Working capital
14.59B13.65B14.72B16.06B12.74B10.08B7.08B5.59B6.52B4.46B2.67B
Book value per share
317.22287.82255.03228.44199.68167.2895.7996.7776.2853.0138.26
Tangible book value
32.18B30.00B28.21B24.93B21.75B18.76B11.03B11.09B8.76B6.14B4.45B
Tangible book value per share
304.76276.24245.05219.30191.62167.2295.7996.7776.2853.0138.26
Current ratio
3.354.134.735.695.063.563.633.675.524.933.15
Debt to equity
0.080.090.090.100.120.140.240.060.080.110.11

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Regeneron Pharmaceuticals's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.